Director at TransMedics (TMDX) receives 2,922 RSU equity grant, holds 5,788 shares

Rhea-AI Filing Summary

Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.

TransMedics Group, Inc. director Edward M. Basile received a grant of 2,922 shares of common stock in the form of restricted stock units. The award was made at no cash cost per share and is a form of equity compensation. Following this grant, Basile directly holds 5,788 shares of the company’s common stock, showing his stake has increased through stock-based awards rather than open-market purchases or sales.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Basile Edward M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,922	$0.00	--

Holdings After Transaction: Common Stock — 5,788 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 2,922 shares Grant price per share: $0.00 per share Shares held after grant: 5,788 shares +1 more

4 metrics

RSU grant size 2,922 shares Restricted stock units awarded to director Edward M. Basile

Grant price per share $0.00 per share Reported transaction price for RSU grant

Shares held after grant 5,788 shares Total common shares directly held after transaction

Transaction date 2026-05-20 Date of RSU award to Edward M. Basile

Key Terms

restricted stock units, RSUs, contingent right, Form 4

4 terms

restricted stock units financial

"Consists of 2,922 restricted stock units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Consists of 2,922 restricted stock units ("RSUs")."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"Each RSU represents a contingent right to receive one share"

Form 4 regulatory

"This Form 4 insider filing reports the equity grant."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Basile Edward M

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		A		2,922(1)	A	$0	5,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TransMedics (TMDX) report for Edward M. Basile?

TransMedics reported that director Edward M. Basile received 2,922 restricted stock units of common stock. This equity award was recorded as a grant at no cash cost per share and increased his directly held position to 5,788 shares.

Was the recent TransMedics (TMDX) insider transaction a purchase or a grant?

The transaction was a grant of 2,922 restricted stock units, not an open-market purchase. Each RSU represents a contingent right to receive one share of TransMedics common stock as part of Basile’s equity-based compensation.

How many TransMedics (TMDX) shares does Edward M. Basile hold after this Form 4?

After the reported grant, Edward M. Basile directly holds 5,788 shares of TransMedics common stock. His position increased due to the 2,922-share restricted stock unit award disclosed in the Form 4 insider filing.

What are the terms of the 2,922 RSUs granted by TransMedics (TMDX)?

The filing states the award consists of 2,922 restricted stock units, each representing a contingent right to receive one share of TransMedics common stock. The grant price is shown as zero, reflecting compensation rather than a cash purchase.

Does the TransMedics (TMDX) Form 4 show any insider share sales?

No insider sales are shown in this Form 4. The filing only reports an acquisition transaction, specifically a grant of 2,922 restricted stock units to director Edward M. Basile, which increased his total directly held shares to 5,788.